Jacobs provided architecture, engineering, construction management and turnover services for Cruiserath Biologics, which has won the Project Execution category at the International Society for Pharmaceutical Engineering (ISPE) 2020 Facility of the Year Awards (FOYA), Jacobs announced on Wednesday.
"With growing demands for its immuno-oncology medicine, Bristol Myers Squibb needed to build a facility for the future," said Koti Vadlamudi, Jacobs Senior Vice President, Advanced Facilities. "The project is a huge success for Jacobs, Bristol Myers Squibb, and ultimately the many patients that rely on these medicines produced in the Dublin campus."
In 2015, Jacobs worked to modernize its existing active pharmaceutical ingredients (API) plant to enable large-scale production of its vital immuno-oncology medicines. Jacobs helped to develop an innovative approach to fighting cancer, immuno-oncology, which has harnessed the body's own immune system to combat tumor cells.
In addition, Jacobs helped create a facility for the $1 billion Multi-Product Cell Culture (MPCC) project. At the time, the project represented the largest pharmaceutical project being undertaken in Europe, with more than 2,200 people on site at peak.
The project's fast-tracked 26-month delivery commanded collaboration from Jacobs' global network of expertise across Ireland, the United States and India, working around the clock to meet the ambitious schedule.
Jacobs provided a detailed project execution plan that was developed to address challenges, monitor progress and ensure project success. The facility was delivered within budget and applied innovative project delivery techniques and tools.
The project has repurposed an existing site to design and construct a new manufacturing facility, global laboratory, offices, cafeteria, utility and warehouse buildings as one functional campus. The facility is now in commercial operation, having recently received regulatory approval from both the FDA and the European Medicines Authority.
"Cruiserath's campus represents the largest ever capital investment for the company and is the first Bristol Myers Squibb biologics manufacturing facility in Europe. We set out with a vision to build a world class Biopharma Campus and state of the art facility, and to receive this highly coveted external and industry recognition indeed signifies we are well on our way," said Cruiserath Biologics general manager and executive director, EU Biologics, Noel Heaney.
At Jacobs, we're challenging today to reinvent tomorrow by solving the world's most critical problems for thriving cities, resilient environments, mission-critical outcomes, operational advancement, scientific discovery and cutting-edge manufacturing, turning abstract ideas into realities that transform the world for good. With $13 billion in revenue and a talent force of more than 55,000, Jacobs provides a full spectrum of professional services including consulting, technical, scientific and project delivery for the government and private sector.